Verastem Oncology has launched a marketing campaign for its co-packaged cancer drug to promote its use in early treatment modalities.
The FDA granted accelerated approval to Avmapki Fakzynja Co-Pack a year ago. Mike Krauser, Verastem’s chief commercial officer, said on an earnings call last month that, as expected, many doctors’ first experience with Corpac often comes later. Verastem hopes to increase the use of Co-Pack in patients experiencing a first recurrence of low-grade serous ovarian cancer (LGSOC).
Boston-based Verastem has launched its “Reimagine” campaign to encourage healthcare professionals (HCPs) and patients to rethink how they treat LGSOC. Verastem is using the ‘Reimagine’ branding across its healthcare worker and patient Co-Pack websites to transform the content it delivers to its audience.
The patient’s website prominently features a video about LGSOC patient Mary. In the video, Mary shares her journey through diagnosis and treatment. When Mary’s cancer returned, she enrolled in a clinical trial of Co-Pack. In the six-minute video, Mary describes the side effects she experienced and the positive response to the treatment.
The effort will be supported by a digital advertising campaign to raise awareness about Co-Pack’s availability and drive traffic to the product website for access to more tools, Crowther said last month. The company is also expanding its education plans by adding peer-to-peer programs.
Verastem reported fourth-quarter Co-Pack net revenue of $17.5 million, bringing the year’s total to $30.9 million. As of February, nearly 300 doctors had prescribed Co-Pack. Because LGSOC is a slow-growing cancer, with patients continuing for several years after initial treatment, Verastem expects it will take time to reach its peak share of first recurrences, Crowther said.
